EMAIL THIS PAGE TO A FRIEND

Virchows Archiv : an international journal of pathology

Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases.


PMID 25048573

Abstract

The clinical course and therapy of mantle cell lymphoma (MCL) are heterogeneous and often unsatisfactory. Prognostic factors are needed to stratify the patients. Microvessel density (MVD) has prognostic significance in some malignancies. There is little information about the vasculature of MCL, although some antiangiogenic drugs are in use. We studied MVD using systematic uniform random sampling and unbiased counting frames in immunohistochemical reactions with anti-CD34 antibody in pre-therapeutic extramedullary MCL samples of 177 patients. We analyzed the relationship of MVD to overall survival (OS) and progression-free survival (PFS), as well as to proliferative activity (Ki-67), mantle cell lymphoma prognostic index (MIPI), morphological variant, pattern of growth, and localization. MVD varied widely: range 54.6-503.6 vessels/mm(2), median 158.2 vessels/mm(2). Higher MVD was associated with bone marrow infiltration at the time of diagnosis (P = 0.001). High MVD was associated with significantly worse OS (P = 0.04) only in patients treated with non-intensive (conventional) therapy. MVD correlated positively with MIPI scores but not with the proliferation, morphological variant, growth pattern, or localization. Univariate analysis identified a prognostic influence of morphological variant, MIPI, and proliferative activity on OS and PFS and a prognostic influence of bone marrow infiltration at the time of diagnosis on PFS. Multivariate analysis showed prognostic influence of MIPI and proliferative activity on OS and PFS only. In conclusion, this is the first clinicopathological study of MVD of MCL with long-term follow-up showing negative prognostic trends of high MVD in MCL and positive correlation of MVD and MIPI.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2100362
Anti-CCND1 (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2100363
Anti-CCND1 (ab2) antibody produced in rabbit, affinity isolated antibody
SAB2100364
Anti-CCND1 (ab3) antibody produced in rabbit, affinity isolated antibody
SAB1405510
Anti-CCND1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2106484
Anti-CCND1 antibody produced in rabbit, affinity isolated antibody
GW10811F Anti-CD34 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB4300690
Anti-CD34 antibody produced in rabbit, affinity isolated antibody
C5588 Anti-Cyclin D1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB4700017 Monoclonal Anti-CCND1 antibody produced in mouse, clone CD1.1, purified immunoglobulin, buffered aqueous solution
SAB5300525
Monoclonal Anti-CCND1 antibody produced in mouse, clone 3D8, ascites fluid
WH0000947M1
Monoclonal Anti-CD34 antibody produced in mouse, clone 5F3, purified immunoglobulin, buffered aqueous solution
SAB1403649
Monoclonal Anti-CD34 antibody produced in mouse, clone 5A6, purified immunoglobulin, buffered aqueous solution
SAB4700160 Monoclonal Anti-CD34 antibody produced in mouse, clone 4H11[APG], purified immunoglobulin, buffered aqueous solution
SAB4700736 Monoclonal Anti-CD34 antibody produced in mouse, clone 581, purified immunoglobulin, buffered aqueous solution
C7464
Monoclonal Anti-Cyclin D1 antibody produced in mouse, clone DCS-6, ascites fluid